# OnCo record egfr-exon-20-insertion (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/egfr-exon-20-insertion/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "egfr-exon-20-insertion" ;
  schema:name "EGFR exon 20 insertion"@en ;
  schema:alternateName "EGFR ex20ins"@en, "exon 20 insertion"@en, "EGFR exon 20 insertion mutation"@en, "EGFR ex20ins NSCLC"@en ;
  schema:description "Exon 20 insertions add amino acids after the C-helix of EGFR and make the kinase resistant to the usual EGFR tablets. They account for about a tenth of EGFR mutations and have their own drugs: amivantamab with chemotherapy and sunvozertinib."@en ;
  schema:url <https://onco.cc/biomarkers/egfr-exon-20-insertion/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8> ;
  onco:tag "biomarker", "egfr" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/her2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/drugs/mobocertinib/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncomine-dx-target-test/> ;
  onco:terms <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/ngs/> .